Cosopt Versus Xalatan

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00273429

Enrollment

Unknown

Registered

2006-01-09

Start date

2005-04-30

Completion date

2005-12-31

Last updated

2007-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-Angle Glaucoma, Ocular Hypertension

Brief summary

To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.

Interventions

DRUGtimolol maleate 0.5%

DRUGdorzolamide/timolol maleate fixed combination

DRUGlatanoprost 0.005%

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion * intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H * ETDRS visual acuity must be 1.0 or better in both eyes

Exclusion criteria

* any contraindications to study medications * any anticipated change in systemic hypertensive therapy during the trial

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026